Primary squamous cell carcinoma of the breast in a young female‐ A rare ailment

Shrestha, Suraj; Shakya, Prafulla; Kharel, Sanjeev; Dhakal, Hari Prasad; Singh, Moushami; Shrestha, Aagon Krishna

doi:10.1002/ccr3.4214

Cited by 4 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our contribution to this sparse body of literature is the presentation of an 80-year-old woman diagnosed with an early-stage pT1 PSCC of the breast who was treated with BCT -a clinical decision that is notably rare in this context. Beyond the SEER data, the literature documents only nine instances of adjuvant radiotherapy following PSCC, with merely four of these cases opting for breast conservation therapy, as summarized in Table 1 [7][8][9][10]. This case underscores the underexplored demographic and clinical pathways for managing early-stage PSCC with BCT and adjuvant radiotherapy.…”

Section: Discussionmentioning

confidence: 97%

Breast Conservation Therapy for Primary Squamous Cell Carcinoma of the Breast in an Elderly Woman: A Case Report

Loving,

Sivapalan,

Schukow

et al. 2024

Cureus

View full text Add to dashboard Cite

This case report details a rare instance of primary squamous cell carcinoma (PSCC) of the breast in an octogenarian, emphasizing the unique diagnostic and treatment challenges posed by this malignancy in an elderly patient and adding to the scientific literature on PSCC managed with breast conservation therapy (BCT). An 80-year-old woman with medical comorbidities presented with a focal asymmetry in the right breast's retroareolar plane, detected during routine screening mammography. Diagnostic evaluations raised high suspicion for malignancy, confirmed as PSCC by ultrasound-guided biopsy. Histopathological analysis showed atypical keratinizing squamous epithelial nests and cysts. The patient underwent lumpectomy and re-excision of close surgical margins with a sentinel lymph node biopsy, which showed well-differentiated invasive squamous cell carcinoma with no residual carcinoma or nodal involvement. She was treated with adjuvant hypofractionated radiation therapy, experiencing minimal side effects. This case highlights the importance of considering individualized, nuanced approaches to adjuvant therapies in the treatment of PSCC in older patients. It demonstrates that BCT, coupled with carefully selected adjuvant therapy, can be a successful treatment strategy for PSCC in the elderly, contributing valuable insights into the management of this rare condition.

show abstract

Section: Discussionmentioning

confidence: 97%

Breast Conservation Therapy for Primary Squamous Cell Carcinoma of the Breast in an Elderly Woman: A Case Report

Loving,

Sivapalan,

Schukow

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Although the patient did not complete the course of neoadjuvant chemotherapy, evaluation of pathologic responses after the neoadjuvant chemotherapy has achieved a good therapeutic effect. In this way, Shrestha et al (22) reported a patient with large breast squamous cell carcinoma treated with a TP regimen and achieved long- term disease-free survival. Thus, it can be seen that the TP regimen might be effective for MSCCB.…”

Section: Discussionmentioning

confidence: 99%

Significant efficacy of paclitaxel plus carboplatin (TP) as a neoadjuvant regimen for metaplastic squamous cell carcinoma of the breast: a rare case report and literature review

Chen¹,

Jiang²,

Luo³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Metaplastic squamous cell carcinoma of the breast (MSCCB) is a rare and aggressive type of cancer. So far, no standard treatment regimen has been established due to the absence of clinical data.Case Description: We report a case of a 48-year-old female admitted to our hospital as a result of a left breast mass with skin rupture. Core needle biopsy under ultrasonic guidance confirmed MSCCB.Immunohistochemistry revealed negative staining for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER2/neu). After receiving 4 cycles of paclitaxel and carboplatin neoadjuvant chemotherapy, the patient was treated with modified radical mastectomy.Postoperative pathology revealed a Miller-Payne score of 4 and no metastasis in the axillary lymph nodes (0/13), indicating a good response to neoadjuvant chemotherapy. She recovered well post-surgery and was discharged to home after admission. No recurrence was identified during the 2 years post-surgery follow-up.Conclusions: MSCCB is a rare and aggressive type of cancer. However, the treatment of MSCCB has not been standardized due to its rarity. Given the observation that the majority of patients with MSCCB had ER, PR, HER2-negative neoplasms, we refer to the triple negative breast cancer (TNBC) treatment protocol.TP regimen was demonstrated to be an effective treatment for TNBC. The results of this case suggest that the TP regimen is effective in neoadjuvant chemotherapy of MSCCB.

show abstract

“…Primary squamous cell carcinoma (PSCC) of the breast is a very rare subtype of saprophytic carcinoma; it accounts for approximately 0.06%-0.2% of all breast cancers (Chen et al, 2022;Wu et al, 2022). PSCC has large tumors, rapid progression, frequent recurrence, and high mortality (Anne et al, 2019;Shrestha et al, 2021). Surgery and radiotherapy can effectively control low-grade squamous cell carcinoma locally (Qi et al, 2021;Wang et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report

Gao

Liao

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Primary squamous cell carcinoma of the breast is a rare subtype of carcinoma of chemosis for which there is no effective chemotherapy regimen. Breast squamous cell carcinoma is usually “triple negative”, with poor chemotherapy effects and poor prognosis. Here, we report a successful case of primary breast squamous cell carcinoma treated with apatinib. The patient was treated with 2 cycles of apatinib. The efficacy was evaluated as partial remission, and a sublesion of approximately 4 cm fell off.

show abstract

Primary squamous cell carcinoma of the breast in a young female‐ A rare ailment

Abstract: Primary squamous cell carcinoma of the breast is an extremely rare invasive breast carcinoma with rapid progression and worse prognosis. Careful assessment and diagnosis of the entity should also be considered in a rapidly progressing breast tumor.

Cited by 4 publications

References 24 publications

Breast Conservation Therapy for Primary Squamous Cell Carcinoma of the Breast in an Elderly Woman: A Case Report

Breast Conservation Therapy for Primary Squamous Cell Carcinoma of the Breast in an Elderly Woman: A Case Report

Significant efficacy of paclitaxel plus carboplatin (TP) as a neoadjuvant regimen for metaplastic squamous cell carcinoma of the breast: a rare case report and literature review

Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report

Contact Info

Product

Resources

About